BIO White Paper Dispels Over-Patenting Myth
Patenting is a Critical Element in Fostering Research and Development
The theory claiming that the over-patenting of biotechnology research hinders the research and development of new treatments is not supported by empirical evidence, concludes a white paper entitled "The Myth of the Anticommons" released by the Biotechnology Industry Organization (BIO). The paper was released as Congress considers a variety of changes to current U.S. patent law.
The theory of the "tragedy of the anticommons," put forth in 1998, claims that patents have the potential to stifle innovation in the biotechnology industry. The theory claims that too many patent holders of upstream technology may inhibit downstream innovation due to transaction costs and strategic behaviors.
The BIO white paper found that the biotechnology industry is actively engaged in discovering and inventing innovative therapies. Research, development and employment in the biotechnology industry are steadily increasing, as are the number of therapies in the clinical pipeline.
The white paper also cited a study by the National Academy of Sciences (NAS) which examined the impact of patents on university research. The NAS study found that only 1% of academic respondents experienced delays on their projects of more than a month due to patents and not a single respondent abandoned a project due to a patent on knowledge inputs.
"Biotech companies and university scientists agree that patents are a key force behind biotech innovation," stated BIO President and CEO Jim Greenwood. "Biotech companies rely on patented intellectual property to attract the funding they need to conduct the years of research and development necessary to bring a product to market and into the hands of patients and other consumers."
"As Congress considers changes to the patent system, we encourage them to recognize and protect the key role patents play in encouraging innovation in the biotechnology industry," concluded Greenwood.
Other news from the department business & finance
Most read news
More news from our other portals
Last viewed contents
Dow acquires Rohm and Haas, creating world's leading specialty chemicals and advanced materials company - $18.8 billion transaction marks pivotal point in Dow's transformation
Cells stop dividing when this gene kicks into high gear
Targeted test for antibiotic resistance in clinical Enterobacter species - New discovery enables targeted antibiotic therapy
Varian, Inc. Announces Unique Probe Technology Breakthrough for Biological Solids NMR
Breakthrough Discovery Sheds Light on Heart and Muscle Health - Scientists shoot first true-to-life 3D image of the thick filament of mammalian heart muscle
Diagnosis just a breath away with new laser
MIT nanotubes sniff out cancer agents in living cells - Chemical engineers use carbon nanotubes to monitor chemotherapy, detect toxins at the single-molecule level
Fishing for DNA to measure biodiversity - Identifying the fish species present in a river based on traces of their DNA: this method has been successfully tested at about 90 sites in Switzerland
BioTek Receives European Patent for Microplate Washer Technology
New high-throughput screening study may open up for future Parkinson's disease therapy
DNA mutations shed in blood predicts response to immunotherapy in patients with cancer
